SOURCE: Duke University, news release, April 4, 2016
MONDAY, April 4, 2016 (HealthDay News) -- A slightly higher dose of radiation therapy for early stage prostate cancer may reduce treatment time without compromising effectiveness, researchers report.
The study included about 1,100 men with early-stage prostate cancer that had not spread beyond the gland. Half received the traditional radiation therapy program of 41 treatments over eight weeks, while the others received slightly higher doses during 28 treatments over about 5.5 weeks.
After five years, cancer-free survival rates were just over 85 percent for those in the traditional group and just over 86 percent for those in the shorter treatment group, while overall survival rates were 93.2 percent and 92.5 percent, respectively.
"This study has implications for public policy," said lead investigator Dr. W. Robert Lee. He is a professor at the Duke Cancer Institute's department of radiation oncology, in Durham, N.C.
"Because the shorter regimen has advantages such as greater patient convenience and lower costs, it's important to establishing whether we can cure as many patients with the shorter regimen. Our study provides that information for the first time," he added in a university news release.
"An estimated 220,000 men are expected to be newly diagnosed with prostate cancer each year in the United States, and the majority will have early-stage disease at low risk for recurrence," Lee said.
The study, published April 4 in the Journal of Clinical Oncology, was partly funded by the U.S. National Institutes of Health and the U.S. National Cancer Institute.
The U.S. Centers for Disease Control and Prevention has more on prostate cancer.